|
|
Article: ImClone's Erbitux Featured In Three Presentations; Stock Dips.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
ImClone Systems Inc. spent the weekend detailing its Erbitux trials at the American Society of Clinical Oncology meeting in Orlando, Fla., and generally worrying investors - the three trials provided mixed results, and ImClone's stock dipped as a result.
ImClone shares (NASDAQ:IMCL) fell $2.29 Monday, or 17.1 percent, to close at $11.12.
New York-based ImClone and its partner, Bristol-Myers Squibb Co., also of New York, said Saturday data were presented by investigators on an Erbitux Phase II trial in combination with cisplatin in treating refractory squamous-cell head and neck cancer. Nine of the 78 evaluable patients in ...